When selecting the appropriate formulation of Livmarli, the patient's weight and ability to swallow tablets should be considered. Livmarli tablets are supplied in 10mg, 15mg, 20mg, and 30mg dosage ...
Researchers found a commercial deworming tablet released only 10% of its drug content in dissolution testing, prompting investigation of new formulations designed to improve drug release and extend ...
Commercially launched in the U.S. in November 2025, TONMYA (cyclobenzaprine HCl sublingual tablets) for long-term daily dosing at bedtime is the ...
The approval was based on data from the phase 1 ELEVATE-PLUS trials, which showed the acalabrutinib 100mg tablets were bioequivalent to the acalabrutinib 100mg capsules. The Food and Drug ...
Phase 3 study designed with total hip BMD primary endpoint assessed at 12 months, rather than at 24 monthsEB613 single tablet final commercial ...
The Phase 2 VENTURE-Oral Dosing Trial is a randomized, double-blind, placebo-controlled multicenter study designed to evaluate the safety, tolerability, pharmacokinetics and weight loss efficacy of ...
BASEL, Switzerland--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use ...
The European Medicines Agency’s human medicines committee has recommended approval of a new tablet formulation of BeOne Medicines’ targeted blood cancer drug Brukinsa (zanubrutinib). The company ...
Roche has announced that a tablet formulation of its spinal muscular atrophy (SMA) treatment Evrysdi (risdiplam) has been approved by the US Food and Drug Administration (FDA). Evrysdi was originally ...
Advanced oral dosage forms allow for modulation of controlled- and sustained-release profiles. Multi-unit pellet systems (MUPS) and intelligently encapsulated mini-tablet systems (EMTS) have unique ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results